BioAtla BCAB Stock
BioAtla Price Chart
BioAtla BCAB Financial and Trading Overview
| BioAtla stock price | 3.91 USD |
| Previous Close | 3.72 USD |
| Open | 3.7 USD |
| Bid | 2.74 USD x 200 |
| Ask | 4.68 USD x 200 |
| Day's Range | 3.6 - 3.89 USD |
| 52 Week Range | 3.12 - 71.5 USD |
| Volume | 15.42K USD |
| Avg. Volume | 50.97K USD |
| Market Cap | 6.34M USD |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -41.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BCAB Valuation Measures
| Enterprise Value | 10.46M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.8578482 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.169748 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 5.231 |
| Enterprise Value/EBITDA | -0.211 |
Trading Information
BioAtla Stock Price History
| Beta (5Y Monthly) | 0.75 |
| 52-Week Change | -80.85% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 71.5 USD |
| 52 Week Low | 3.12 USD |
| 50-Day Moving Average | 3.91 USD |
| 200-Day Moving Average | 18.54 USD |
BCAB Share Statistics
| Avg. Volume (3 month) | 50.97K USD |
| Avg. Daily Volume (10-Days) | 64.03K USD |
| Shares Outstanding | 1.66M |
| Float | 1.37M |
| Short Ratio | 2.23 |
| % Held by Insiders | 5.45% |
| % Held by Institutions | 22.50% |
| Shares Short | 151.85K |
| Short % of Float | 9.46% |
| Short % of Shares Outstanding | 9.15% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2494.94% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -133.11% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 2M USD |
| Revenue Per Share (ttm) | 1.59 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -32900000 USD |
| EBITDA | -49589000 USD |
| Net Income Avi to Common (ttm) | -50617000 USD |
| Diluted EPS (ttm) | -41.56 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.96M USD |
| Total Cash Per Share (mrq) | 1.18 USD |
| Total Debt (mrq) | 6.09M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.149 |
| Book Value Per Share (mrq) | -22.481 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -37183000 USD |
| Levered Free Cash Flow (ttm) | -18408876 USD |
Profile of BioAtla
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 11085 Torreyana Road |
| ZIP | 92121 |
| Phone | 858 558 0708 |
| Website | https://www.bioatla.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Q&A For BioAtla Stock
What is a current BCAB stock price?
BioAtla BCAB stock price today per share is 3.91 USD.
How to purchase BioAtla stock?
You can buy BCAB shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioAtla?
The stock symbol or ticker of BioAtla is BCAB.
Which industry does the BioAtla company belong to?
The BioAtla industry is Biotechnology.
How many shares does BioAtla have in circulation?
The max supply of BioAtla shares is 1.66M.
What is BioAtla Price to Earnings Ratio (PE Ratio)?
BioAtla PE Ratio is now.
What was BioAtla earnings per share over the trailing 12 months (TTM)?
BioAtla EPS is -41.56 USD over the trailing 12 months.
Which sector does the BioAtla company belong to?
The BioAtla sector is Healthcare.
BioAtla BCAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25873.18 USD — |
-1.55
|
6.31B USD — | 25822.1 USD — | 26139.37 USD — | — - | 6.31B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2276 USD — |
-2.23
|
— — | 2272.18 USD — | 2307.6 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6546.6 USD — |
-1.47
|
— — | 6508.46 USD — | 6585.47 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1254.95 USD — |
-1.05
|
— — | 1250.11 USD — | 1262.34 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}